These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 38455854)
21. Management of carcinoid syndrome: a systematic review and meta-analysis. Hofland J; Herrera-Martínez AD; Zandee WT; de Herder WW Endocr Relat Cancer; 2019 Mar; 26(3):R145-R156. PubMed ID: 30608900 [TBL] [Abstract][Full Text] [Related]
22. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY. Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI; Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049 [TBL] [Abstract][Full Text] [Related]
23. Carcinoid syndrome: diagnosis and medical management. van der Lely AJ; de Herder WW Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):850-60. PubMed ID: 16444370 [TBL] [Abstract][Full Text] [Related]
24. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146 [TBL] [Abstract][Full Text] [Related]
26. Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies. Vitale G; Carra S; Alessi Y; Campolo F; Pandozzi C; Zanata I; Colao A; Faggiano A; On Behalf Of The Nike Group Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835022 [TBL] [Abstract][Full Text] [Related]
27. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of Lodge MA; Solnes LB; Chaudhry MA; Wahl RL Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361 [TBL] [Abstract][Full Text] [Related]
28. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997 [TBL] [Abstract][Full Text] [Related]
29. Hepatic surgery for metastases from neuroendocrine tumors. Sarmiento JM; Que FG Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141 [TBL] [Abstract][Full Text] [Related]
31. Value of [ Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900 [TBL] [Abstract][Full Text] [Related]
32. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778 [TBL] [Abstract][Full Text] [Related]